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Various types of non-neuronal cells, including tumors, are able to produce acetylcholine
(ACh), which acts as an autocrine/paracrine growth factor. T lymphocytes represent a
key component of the non-neuronal cholinergic system. T cells-derived ACh is involved
in a stimulation of their activation and proliferation, and acts as a regulator of immune
response. The aim of the present work was to summarize the data about components
of cholinergic machinery in T lymphocytes, with an emphasis on the comparison of
healthy and leukemic T cells. Cell lines derived from acute lymphoblastic leukemias of
T lineage (T-ALL) were found to produce a considerably higher amount of ACh than
healthy T lymphocytes. Additionally, ACh produced by T-ALL is not efficiently hydrolyzed,
because acetylcholinesterase (AChE) activity is drastically decreased in these cells.
Up-regulation of muscarinic ACh receptors was also demonstrated at expression and
functional level, whereas nicotinic ACh receptors seem to play a less important role and
not form functional channels in cells derived from T-ALL. We hypothesized that ACh
over-produced in T-ALL may act as an autocrine growth factor and play an important
role in leukemic clonal expansion through shaping of intracellular Ca2+ signals. We
suggest that cholinergic machinery may be attractive targets for new drugs against
T-ALL. Specifically, testing of high affinity antagonists of muscarinic ACh receptors as
well as antagomiRs, which interfere with miRNAs involved in the suppression of AChE
expression, may be the first choice options.
Keywords: acetylcholine, acetylcholinesterase, calcium signaling, choline acetyltransferase, muscarinic receptor
non-neuronal cholinergic system, T leukemia, T lymphocyte
Abbreviations: 4-DAMP, 4-diphenyl acetoxy-N-methyl-piperidine; ACh, acetylcholine; AChE, acetylcholinesterase; AChR,
ACh receptors(s); ALL, acute lymphoblastic leukemia; B-ALL, ALL of B cell lineage; BChE, butyrylcholinesterase; BM, bone
marrow; Ca2+, calcium; ChAT, choline acetyltransferase; CHT1, high-affinity choline transporter 1; Cn, calcineurin; CTL1-
5, intermediate-affinity choline transporter-like proteins; CRAC, Ca2+ release activated channels; DCs, dendritic cells; ER,
endoplasmic reticulum; IL-2, interleukin-2; IL-2R, IL-2 receptor(s); IP3, inositol-1, 4, 5-trisphosphate; mAChR, muscarinic
ACh receptor(s); MAPK, mitogen-activated protein kinase; MicroRNAs, miRNAs; MNLs, mononuclear leukocytes; MRS,
magnetic resonance spectroscopy; nAChR, nicotinic ACh receptor(s); NFATs, nuclear factor of activated T cells; NNCS,
non-neuronal cholinergic system; NSCLC, non-small-cell lung cancer; OCT, organic cation transporter; P-F-402, HHSiD
parafluorohexahydrosiladifenidol; PHA, phytohemagglutinin; PKA, protein kinase A; PKC, protein kinase C; PLC,
phospholipase C; PMA, phorbol 12-myristate acetate; SCLC, small cell lung carcinoma; STIM1, stromal interaction molecule
protein 1; T-ALL, ALL of T cell lineage; TCR, T cell receptor(s); VAChT, vesicular ACh transporter.
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INTRODUCTION
Acute lymphoblastic leukemia is the most common type of cancer
in infants and a leading cause of cancer-related deaths in children
(Ward et al., 2014). Although T-ALL is 5–6 times less common
than B-ALL, it is characterized by a worse prognosis, especially
dismal in case of a relapse (Nguyen et al., 2008). Obviously, search
for new efficient therapies for T-ALL needs to be continued.
Traditionally, the cholinergic system was considered specific
to nerve cells that produce ACh and use it as a neurotransmitter.
However, it is widely accepted nowadays that ACh, as a
functionally important compound, evolutionarily predates the
development of a nervous system. ACh plays important autocrine
and paracrine functions in physiology of many types of non-
neuronal cells. Accordingly, the concept of a “NNCS” is widely
used (Kawashima and Fujii, 2003). Particularly, ACh was
shown to be involved in proliferation, apoptosis, and cellular
migration. Noteworthy, all these processes are fundamental for
tumorigenesis, and there is growing evidence that the cholinergic
signaling is an essential component in pathogenesis of various
malignancies (Shah et al., 2009).
A variety of cellular types in the immune system, such as T
lymphocytes, granulocytes, macrophages, mastocytes, and DCs
have been reported to express the ACh-synthesizing enzyme
ChAT; all immune cells, including T and B cells, macrophages
and DC, express several subtypes of AChR (Kawashima and Fujii,
2000, 2003, 2004; Kawashima et al., 2015). However, the patterns
of cholinergic elements vary considerably among different
lymphocyte lineages and leukemic cell lines (Kawashima and
Fujii, 2000, 2004; Fujii et al., 2008). There is accumulated evidence
for the involvement of the cholinergic pathway in modulation
of the immune response, by means of its effect on lymphocyte
proliferation and differentiation, cytokine production, antigen
presentation, and inflammation (Ofek and Soreq, 2013).
T cells are considered to be the main source of the ACh
in blood, and they were proposed to represent an independent
cholinergic system (Kawashima et al., 2012). There is a vast array
of relevant data obtained on human MNLs, isolated T cells and
leukemic cell lines derived from T-ALL. It was demonstrated
that the ACh pathway represents an essential segment in calcium
(Ca2+) signaling of T cells. At the same time, T-ALL pathogenesis
is associated with an aberrant Ca2+ signaling (Bhojwani et al.,
2015; Dobrovinskaya et al., 2015). Yet, to our best knowledge, no
systematic attempts have been undertaken to link T lymphocyte
cholinergic system with T leukemogenesis. In the present paper
we will focus on the comparison of cholinergic system in healthy
and leukemic T cells, to reveal the potential of this pathway as a
pharmacological target in T cell derived neoplasias.
T CELLS AS IMPORTANT COMPONENTS
OF NON-NEURONAL CHOLINERGIC
SYSTEM
As ACh is a short-lived compound, which is rapidly degraded by
AChE and BChE, its presence in considerable amounts in blood
of mammals argued for its origin from blood cells rather than
from neurons. Indeed, about 60% of blood ACh originates from
lymphocytes, and T lymphocytes are considered authentically
cholinergic (reviewed in Kawashima and Fujii, 2000, 2004).
Further in this review, the expression patterns of cholinergic
elements in different lymphoid lineages and cell lines will be
considered.
Choline Uptake
Choline is a precursor for the ACh synthesis, as well
for the synthesis of major membrane phospholipids,
phosphatidylcholine, and sphingomyelin. Accordingly, any
cell possesses the machinery for choline transport. Respective
transporters belong to three distinct families: (1) CHT1; (2)
CTL1-5; (3) polyspecific OCT with a low affinity for choline
(Michel et al., 2006). Since the rate limiting step in the ACh
synthesis is the uptake of choline, expression of choline
transporters of high affinity seems to be required for effective
ACh production. In nerve terminals, choline is exclusively taken
up by CHT1 (Kuhar and Murrin, 1978). Although no data
are available for isolated healthy human lymphocytes, robust
presence of CTL1 protein in human spleen, as shown by Western
blot, is indicative that normal T cells may express CTL1(Michel
et al., 2006). Functional expression of high affinity CHT1
was demonstrated in leukemic cell line MOLT-3 (Fujii et al.,
2003), which is characterized by extremely high ACh content
(∼250 pmol/106 cells) as compared to the leukemic lines CEM
and Jurkat,∼12.6 and 8 pmol/106 cells, respectively (Kawashima
and Fujii, 2004). Notably, CEM and Jurkat T cells did not express
CHT1 (Fujii et al., 2003). Jurkat cells were reported recently
to express intermediate-affinity CTL1 (Inazu, 2014). Thus, an
elevated level of the ACh production in leukemias may be related
to the expression of the CHT1.
Acetylcholine Synthesis
Cytoplasmic ChAT is the primary enzyme that catalyzes both
neuronal and non-neuronal ACh production from choline and
acetyl coenzyme A. The presence of ChAT mRNA and protein
has been detected in human and murine MNL, rat lymphocytes,
human leukemic T cell lines, but, importantly, not in B cells (Fujii
et al., 1995, 1998, 1999; Rinner et al., 1998; Kawashima et al.,
2007). Unstimulated human CD4+, but not CD8+ T cells, express
ChAT mRNA (Fujii et al., 1999).
Mitogenic stimulation with PHA potentiated activity of ChAT,
ACh synthesis and release in human MNL and leukemic T cell
lines, implicating the involvement of the cholinergic machinery
in the regulation of the T cell activation and proliferation (Fujii
et al., 1996, 1998, 2012a,b; Kawashima and Fujii, 2000). PHA is
known to activate T cells through up-regulation of PLC-mediated
production of the inositol-1, 4, 5-trisphosphate (IP3), followed by
intracellular Ca2+ rise, and, in turn activation of Ca2+-dependent
phosphatase calceneurin (Cn) and cascades of PKC and MAPK
(Lichtman et al., 1983). A non-specific PKC activator PMA and
the PKA activator dibutyryl cAMP were shown to up-regulate
the ChAT activity, ACh synthesis and release from T leukemic
cells MOLT-3. Cn inhibitor FK506 suppressed the PHA-induced
ChAT mRNA expression, suggesting that Ca2+/Cn-mediated
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pathway is involved in the process of ACh synthesis in MOLT-3
cells (Fujii et al., 2012b).
Stimulation of T cells with ICAM-1, an intercellular adhesion
molecule binding to the integrin CD11a, also up-regulates ChAT
expression and ACh synthesis in T cells. Similar results were
obtained with monoclonal antibodies against CD11a. Thus, the
interaction of T cells with the activated vascular endothelium
or other immune cells, such as macrophages, up-regulates the
lymphocytic cholinergic activity (Kawashima et al., 2012).
Notably, as demonstrated in a rat model, T cells express
ChAT and produce ACh from the early stages of maturation
in thymus. It was suggested that ACh may serve as a mediator
between maturating thymocytes and thymic stroma, and regulate
apoptosis during positive and negative selection. Furthermore,
ACh production increased after the mitogenic stimulation of
isolated thymocytes in vitro (Rinner et al., 1999).
Acetylcholine Release
In cholinergic neurons, ACh is synthesized in the cytosol and
then transported into synaptic vesicles by VAChT, where it
remains stored until a specific stimulation takes place (Varoqui
and Erickson, 1996). ACh release from the cholinergic nerve
terminals may be mediated by the exocytosis, evoked by cytosolic
Ca2+ increase caused by membrane depolarization during an
action potential, or alternatively, by synaptosomal membrane
protein mediatophore, which translocates ACh in response to
Ca2+ challenge (Israël et al., 1986, 1994, 1998; Cavalli et al., 1991;
Malo and Israël, 2003; Dunant et al., 2009).
A non-neuronal VAChT was described in human SCLC, where
a specific VAChT inhibitor vesamicol notably attenuated ACh
release and cell proliferation (Song et al., 2003). However, there
is no evidence for the presence of VAChT mRNA in human
healthy lymphocytes or leukemic cell lines. It was proposed that,
in contrast to neurons, lymphocytes synthesize and liberate ACh
without storage (Fujii et al., 2008). Some plasma membrane
proteins were shown to facilitate ACh liberation by translocation,
like synaptosomal mediatophore mentioned above (Israël et al.,
1986, 1994, 1998; Cavalli et al., 1991; Malo and Israël, 2003;
Dunant et al., 2009) or OCT in human placenta and urothelium
(Wessler et al., 2001; Kummer et al., 2006). In leukemic T cell
lines CEM and MOLT-3, the presence of mediatophore, but not
of OCT mRNA was shown. Activation with PHA significantly up-
regulates ChAT and mediatophore expression in these cells, with
a subsequent synthesis and release of ACh (Fujii et al., 2012a).
Since meditophore releases ACh in a Ca2+- dependent manner
(Dunant et al., 2009), one can suggest that physiological events,
which provoke intracellular Ca2+ rise in lymphocytes (antigen
activation and clonal expansion) may intensify the ACh release.
However, this hypothesis needs to be proved experimentally. To
date, there is no available information regarding mediatophore
involvement in the ACh release by T cells derived from healthy
donors.
AChE Expression
Signaling events, mediated by ACh, are terminated, when ACh is
hydrolyzed by the AChE and by a less specific BChE. Hence, to be
able to regulate ACh level in nearby microenvironment, immune
cells themselves should express ACh degrading enzymes. Indeed,
classical studies undertaken with normal human peripheral blood
lymphocytes demonstrated that T but not B cells populations
possess high AChE enzymatic activity (Szelényi et al., 1982).
The enzyme was shown to be membrane-bound and present in
homogenous dimeric form (Bartha et al., 1987). More recently,
expression of three different types of the AChE mRNAs has been
detected in leukemic cell lines of T (CEM) and B (Daudi) lineages
as well as in human peripheral blood lymphocytes (Tayebati et al.,
2002).
Up-regulation of the AChE by PHA was reported in T cells
(Szelényi et al., 1982; Kawashima et al., 2015). Accordingly, T cells
activation is accompanied not only by an increased ACh synthesis
and up-regulation of AChR expression, but also by the activation
of their own ACh degradation mechanism. These findings further
support the idea that T cells possess an independent cholinergic
machinery.
Detailed studied carried out on 56 leukemic cell lines have
demonstrated that AChE activity was significantly lower in cell
lines derived from patients with T-ALL, when compared with
cell lines originated from adult T cell leukemia (Rubinstein et al.,
1984). Accordingly, the authors suggested that AChE activity may
represent a maturation feature of T cells.
Cholinergic Receptors and the
Regulation of Immune Function
In accord with a binding affinity for two naturally occurred
substances, muscarine or nicotine, cholinergic receptors are
classified into two categories, muscarinic (mAChR) or nicotinic
(nAChR), respectively, which possess no structural similarity one
with another, although both could be activated by ACh.
Muscarinic belong to a class I subfamily of G-protein
coupled receptors with seven conserved transmembrane domains
and are represented by five distinct subtypes, M1-5 (Caulfield
and Birdsall, 1998; Ishii and Kurachi, 2006). M1, M3, and
M5 receptors are preferentially coupled to the Gq/11 subunit
of G-proteins, with resulting stimulation of PLC-mediated
production of the IP3 and subsequent increase of the intracellular
Ca2+ concentration (Nahorski et al., 1997). In contrast, M2
and M4 are coupled mainly to G proteins of the Gi/o
classes, typically leading to the adenylate cyclase inhibition
and activation of inward-rectifier potassium channels (Yamada
et al., 1998; Volpicelli and Levey, 2004). mAChR subtypes can
regulate a wide network of signaling intermediates, including
small GTPase Rho, phospholipase D, phosphoinositide-3 kinase,
non-receptor kinases, and MAPKs (Kozma et al., 1997;
Schmidt et al., 1997; Firth and Jones, 2001; Linseman et al.,
2001).
Nicotinic nAChRs are pentameric complexes consisting either
of α (1-10) subunits, homomeric (in case of α7 and α9) or
heteromeric ones, or of a combination of α and β subunits (in
muscle tissue δ, ε, and γ subunits may be present as well). In
neurons and muscle nAChRs form a ligand (ACh and nicotine)-
gated cation channels. Depending on the subunit composition,
these channels display a different sensitivity to agonists and
a different degree of Ca2+/Na+ selectivity, with homomeric
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α7 complex being the most Ca2+-selective and less nicotine-
sensitive (Russo et al., 2014; Zhao, 2016 and references therein).
Most immune cells express several subtypes of both mAChR
and nAChR. The presence of AChR in normal rodent and
human lymphocytes was confirmed in numerous binding studies
using radiolabeled ACh, nicotine and specific muscarinic or
nicotinic antagonists (reviewed in Kawashima and Fujii, 2000).
Such radioligands, however, are not selective for special receptor
subtypes. The expression of mRNA encoding AChR subtypes in
human MNL from healthy donors was analyzed by Sato et al.
(1999). Although, the presence of at least some mAChR and
nAChR subtypes was detected in all samples, the expression
pattern varied significantly among individuals. M4 and M5
mAChR, and nAChR subunits α2, α5, and α7 were present in
all samples (7/7); in some samples were also present M1 (5 of
7), M2 (5 of 7), M3 (5 of 7), α6 (2 of 7), β2 (3 of 7). These data
evidenced the diversity of cholinergic system in human immune
cells, where each person may respond to ACh stimulation in
a different way. It was proposed that the expression pattern
may be genetically determined or regulated by some factors
such as infection and physiological stress (Kawashima and Fujii,
2000). It was found that levels of α5 and α7 nAChR subunits
expression were significantly decreased in peripheral MNL from
smokers, when compared with those from non-smokers (Fujii
et al., 2008).
Immunohistochemical analysis and reverse transcription-
polymerase chain reaction (RT-PCR) of MNL has shown the
presence of several α and β isoforms like α3, α4, α5, α7, α9,
α10, β1, and β2 (Hiemke et al., 1996; Lustig et al., 2001; Peng
et al., 2004; Wongsriraksa et al., 2009). In isolated T cells
populations, the expression of α2, α5, α6, α7, α9, α10, and β2
isoforms was revealed at mRNA and protein levels by RT-PCR
and immunohistochemical analysis, respectively (Toyabe et al.,
1997; Lustig et al., 2001). Caution should be paid to results on the
occurrence of specific α-nAChR subunits, obtained exclusively by
means of commercial antibodies. The latter, as shown in mice
with a null mutation for a single nAChR subunit, also label
collateral targets, with a level of immunoreactivity very similar
to wild type (Moser et al., 2007). It was recommended, therefore,
to employ alternative strategies and use, for instance, conjugated
specific antagonists, like α -bungarotoxin (α -BTX; Jones and
Wonnacott, 2005).
Reverse transcription-polymerase chain reaction analyses of
nAChR in thymocytes subsets and T cells indicated that during
the process of thymocyte maturation there is a down-regulation
of α2 and α5, denoting their possible role in T cell development
(Kawashima et al., 2012). Plasticity of the T-cell cholinergic
receptors during differentiation was also demonstrated in murine
model (Qian et al., 2011).
It is well-known that nAChR form ligand (ACh and nicotine)-
gated cation channels in neurons and muscles. To better
understand the physiological significance of these receptors
in lymphocytes, single-cell records were attempted on both B
and T subsets using standard patch-clamp techniques (Peng
et al., 2004). However, lymphocytes recordings did not show
any current response to a stimulation with ACh, nicotine or
cholinergic receptor agonist carbachol. Then, nAChR may have
a different mode of action in lymphocytes (Peng et al., 2004).
Non-channel function of α7 nAChR in human lymphocytes
seems to be caused by partial duplication of the gene
CHRNA7 coding for α7. Resulting new gene, human – specific
CHRFAM7A, codes α7 duplicate nicotinic AChR- related protein
(dupα7). Dupα7 assembles with α7 subunits (α7dupα7), but does
not exhibit ACh or nicotine binding sites (Villiger et al., 2002).
Expression of α7 and dupα7 in a 1:1 molar ratio in oocytes
resulted in a decrease of ACh-stimulated current by more than
30%, suggesting that the CHRFAM7A gene product (dupα7)
is a dominant-negative regulator of α7 ion channel function
(Araud et al., 2011; De Lucas-Cerrillo et al., 2011). Human
peripheral blood lymphocytes were shown to express large
amounts of dupα7/CHRFAM7A, but little to no α7/CHRNA7
mRNA (Costantini et al., 2015a,b). High level of CHRFAM7A
mRNA expression was detected also in purified population of
human CD4+ T-lymphocytes (Rozycka et al., 2013). It was
hypothesized that CHRFAM7A play significant role in human
leukocyte biology. Specifically, the ratio of CHRFAM7A and
CHRNA7 expression may be important in defining the human
α7 function (Costantini et al., 2015a,b). As the CHRFAM7A
gene is human-specific, the findings on α7 nAChR expression
and function obtained in animal models should be taken with
precaution and cannot be extrapolated to humans.
Although the underlying mechanisms are not well-
understood, there is little doubt about the functionality of
activated AChR in lymphocytes. Upon stimulation of healthy
T cells with Con A, PHA, or nicotine the expression of α7 was
up-regulated (De Rosa et al., 2005, 2009; Razani-Boroujerdi
et al., 2007; Landais et al., 2010). ACh and muscarinic agonists
stimulated DNA and RNA synthesis, IP3 accumulation, and
lymphocyte proliferation in humans and rodents (reviewed in
Kawashima and Fujii, 2000). Nicotine regulates cell proliferation,
differentiation, migration, cell–cell interactions, and apoptosis
(De Rosa et al., 2005, 2009; Liu et al., 2014). ACh and synthetic
mAChR agonists insensitive to AChE hydrolysis, as well as
muscarinic antagonists, were used to demonstrate that M3
and/or M5 stimulation induces transient intracellular Ca2+
rise, followed by extracellular Ca2+-dependent oscillations
and up-regulation of the c-fos expression in T and B cells
(Fujii and Kawashima, 2000a). Using AChR knockout mice,
it was found that the M1/M5 pathway up-regulates IgG1 and
pro-inflammatory cytokine production, while the α7 nAChR
linked signaling has the opposite effect (Fujii et al., 2007;
Kawashima et al., 2015). CD8+ T cells from M1-deficient mice
show a defect in their ability to differentiate into cytolytic T
lymphocytes (Zimring et al., 2005). Since muscarinic agonist
Oxo-M stimulates the production of interleukin-2 (IL-2) and
up-regulates the expression of IL-2 receptors (IL-2R) in PHA-
stimulated T cells, it was proposed that ACh acts as an autocrine
factor (reviewed in Kawashima and Fujii, 2003). It was postulated
that the T-cell derived ACh, functioning via autocrine/paracrine
pathways may be involved in the regulation of immune function
(reviewed in Kawashima et al., 2015). However, there is as yet no
in vivo direct evidence demonstrating that T cell- derived ACh
Frontiers in Pharmacology | www.frontiersin.org 4 August 2016 | Volume 7 | Article 290
fphar-07-00290 August 29, 2016 Time: 12:37 # 5
Dobrovinskaya et al. Targeting Cholinergic Machinery in T-leukemias
binds to AChR on the same cell or neighboring cells, to exert this
modulating effect.
Figure 1A depicts our current understanding of possible
cellular targets for the T-cell derived ACh. However, it must
be kept in mind that various cell lineages from CD4+
cell microenvironment may also produce ACh and that real
interactions are more complex.
Acetylcholine-Producing T Cells are Key
Regulators in the Cholinergic
Anti-inflammatory Pathway
The cholinergic anti-inflammatory pathway, also termed as
inflammatory reflex, together with anti-inflammatory cytokines,
glucocorticoids, and other humoral mediators, is involved
in the suppression of inflammatory response (Tracey, 2002).
An excellent critical review highlighting the evolution in the
understanding of underlying mechanisms was published recently
(Martelli et al., 2014). Here, we only briefly present this well-
studied example, to emphasize the potential of the T cell NNCS
in mammal physiology.
During the inflammation, pro-inflammatory cytokines
activate afferent sensory neurons, which represent the sensory
arc of the inflammatory reflex. Axons traveling in the vagus
nerve transmit this information as action potentials to the brain
stem. The brain stem generates inhibitory signals, which traverse
the efferent vagus nerve into the spleen. This efferent arc actually
represents a cholinergic anti-inflammatory pathway. Electrical
stimulation of splenic nerve was believed to result in release of
ACh into splenic tissue and into the eﬄuent splenic vein, with
a subsequent down regulation of the inflammatory cytokines
(Tracey, 2009). Rosas-Ballina et al. (2011) showed that the ACh
released in response to vagal stimulation was not neural in its
origin. Using a murine model, they demonstrated that ACh was
produced by a subset of T lymphocytes, present in the spleen
(Rosas-Ballina et al., 2011; Gautron et al., 2013). Consequently,
in nude mice, lacking functional T cells, vagal stimulation had no
anti-inflammatory effect, whereas it was restored by the adoptive
transfer of ACh-synthesizing T lymphocytes (Rosas-Ballina et al.,
2011). Direct binding of the ACh to α7 nAChR on macrophages
was proposed (Rosas-Ballina et al., 2011). However, according to
a more recent model, ACh liberated from mobilized T cells binds
primarily to the essential α7 nAChR on the peripheral terminals
of the splenic sympathetic nerves and stimulates noradrenaline
release (Martelli et al., 2014). Noradrenaline in turn acts on
β-adrenergic receptors on splenic macrophages, with a resulting
suppression of the TNF-α production. Direct binding of ACh
to α7 nAChR on macrophages is also possible (Rosas-Ballina
et al., 2011; Martelli et al., 2014). In this way, the production of
ACh by T cells provides a reliable protective mechanism from
inflammatory damage in mammals.
TCR- and Muscarinic (M1, 3, 5)
Receptor- Triggered Signaling Pathways
are Cross-Linked in T Cells
Mature naïve or memory T cells are activated following
recognition and binding of TCR to a specific antigen, presented
FIGURE 1 | Current view on T cell NNCS in regulation of immune
function. (A) Proposed paracrine and autocrine effect of T cell-derived ACh in
T cell microenvironment. (B) Role of NNCS in Ca2+ signaling and gene
expression in healthy T-lymphocyte. (A) TCR- and muscarinic (M1, 3, 5)
receptor- triggered signaling pathways are cross-linked in T cells. In healthy
T-cells, principle route of phospholipase C (PLCγ) activation upon recognition
of antigen-presenting cell occurs via TCR/CD3 complex. TCR –generated
signal is amplified by a co-receptor (CD4), which recruits Lck, a tyrosine
kinase, phosphorylating several targets, including Z-chain protein kinase
ZAP70, which phosphorylates LAT (linker for activation of T-cells), interacting
with PLCγ. PLCγ may be activated through alternative mechanism related to
T cell cholinergic system, where import of choline (Cho), synthesis of ACh and
its secretion via yet unknown pathway results in paracrine/ autocrine
activation of muscarinic receptors M1, M3 and/or M5. It follows by activation
of trimeric G-protein (Gq11), whose subunit α activates PLCγ. PLCγ degrades
phosphatidylinositol 4,5-bisphosphate (PIP2) into soluble IP3 and membrane
bound diacylglycerol (DAG). Intracellular release of IP3 activates IP3
receptor-channel, mediating Ca2+-release from ER. Ca2+ depletion of
reticulum is sensed by STIM1 of ER membrane, which promotes assembly of
Orai subunits and formation of CRAC channel in the plasma membrane, the
main route of capacitive Ca2+ entry, which considered to be principle Ca2+
influx channel in lymphocytes. CRAC-mediated Ca2+ influx is sustained, when
membrane negative potential difference is maintained due to K+ efflux via a
set of K+-selective channels, in healthy T-cells represented by
voltage-dependent Kv1.3 channel and Ca2+-activated intermediate
conductance K+ channel KCa3.1. Activation of calcineurin (CN) via
Ca2+/calmodulin (CaM) complex occurs only upon prolonged intracellular
Ca2+ increase. Principle target of CN is NFATs, heavily phosphorylated at the
rest; its dephosphorylation make it permeable via nuclear pore. By entering
nucleus, NFAT induces the transcription of several genes.
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by infected or professional antigen-presented cells. This initial
event triggers the signaling cascade, which includes activation
of the PLCγ, hydrolysis of phosphatidylinositol 4,5-bisphosphate
(PIP2) with the release of IP3, IP3 binding to its receptor in the
ER, initial Ca2+ release from ER with a subsequent activation
of CRAC of the cell membrane and a complex modulation
of Ca2+ signaling, leading to the Cn activation. NFATs is a
principal Cn target in T lymphocytes. NFAT dephosphorylation
and translocation to nucleus as well as the activation of PKC
and MAPK cascades culminate in changes of the transcriptional
activity and proliferation of an antigen-specific clone (Lichtman
et al., 1983; Weiss and Littman, 1994).
Among genes up-regulated during T cell activation, IL-2
and IL-2R are of special importance for a clonal expansion.
Signaling through TCR/CD3 stimulates both ACh production
and its release from T cells, as demonstrated in experiments
with T cells, treated with PHA, which crosslinks TCR (Fujii
et al., 1998; Kawashima and Fujii, 2000; Fujii et al., 2012b).
In turn, lymphocyte-derived ACh acts in an autocrine and/or
paracrine manner, via binding to the AChR on the cellular
surface. Muscarinic receptors M1, M3, and M5 are coupled
to Gq/11 type G proteins and activate PLC, which releases
IP3. In a variety of experimental systems, cholinergic agonists
caused intracellular Ca2+ rise and c-fos expression (Fujii and
Kawashima, 2000a,b,c; Kawashima and Fujii, 2003) and led to the
expression of both IL-2 and IL-2R in T lymphocytes (Rinner et al.,
1995; Kawashima and Fujii, 2000, 2003; Nomura et al., 2003).
Activation of these receptors has been linked to the control of
MAPK and, as a consequence, to the regulation of cell growth
and proliferation (Gutkind, 1998; Gudermann et al., 2000).
Accordingly, signaling events of the both mentioned pathways
appear to be cross-linked, with the autocrine stimulation by ACh
creating an amplifying loop in the TCR signaling (Figure 1B).
CHOLINERGIC SIGNALING MAY BE
INVOLVED IN T LEUKEMOGENESIS
T leukemogenesis is a multistep process, where genetic
aberrations during the T cell maturation convert healthy T cell
progenitors into leukemic cells that are unable to differentiate,
but demonstrate high potential of self-renewal and proliferation.
Due to multiple mutations, T-ALL are heterogeneous and
multiclonal. Molecular basis of T-ALL pathogenesis is a subject
of intensive studies and is reviewed exhaustively elsewhere
(Graux et al., 2006; Van Vlierberghe and Ferrando, 2012; Hales
et al., 2014; Durinck et al., 2015). Among most frequent and
prominent abnormalities are activating mutations in NOTCH1,
IL7R/JAK, and PI3K/Akt/mTOR pathways. The majority of
signaling pathways, up-regulated by leukemogenic mutations,
strongly depend on Ca2+ signaling (reviewed in Dobrovinskaya
et al., 2015). For example, the NOTCH1- dependent Cn–NFAT
axis, aberrantly activated in over 50% of pediatric T-ALL (Weng
et al., 2004), requires a sustained elevation of intracellular Ca2+
(Medyouf et al., 2007; Gachet et al., 2013).
As described in previous chapters, the cholinergic system is
involved in the regulation of Ca2+ signaling in lymphocytes.
Importantly, T cell progenitors show the presence of a cholinergic
autocrine/paracrine loop from the earliest stages of maturation
(Rinner et al., 1999). This mechanism may be retained in
aberrant leukemic progenitors, and involved in the maintenance
of an increased proliferation level. In this chapter we will
first provide a summary on the expression and function of
cholinergic elements in tumors of different origin, and then
present the data, available for T-ALL. We will also discuss a
possible relation between genetic aberrations and cholinergic
machinery during T leukemogenesis. Special emphasis will be
put on a potential role of the cholinergic autocrine/paracrine
loop in a shaping of Ca2+ signal and on the involvement of
cholinergic signaling in interactions between leukemic T cells and
their microenvironment in the BM.
Cholinergic Signaling in Cancer
An enhanced level of choline uptake and metabolism is obviously
required for actively proliferating tissues, because choline is
needed for a rapid biosynthesis of cell membranes. Elevated
concentrations of choline and its metabolites were revealed by
means of MRS in a wide variety of malignances (reviewed in
Inazu, 2014). Accelerated choline metabolism was considered as a
metabolic hallmark that is associated with malignant progression
(reviewed in Glunde et al., 2011). Nowadays, MRS method
which determines elevated local concentrations of choline and its
metabolites is widely used to assist the diagnosis and staging of
cancer, and evaluate the therapeutic response (Hara et al., 1997,
1998, 2000; Glunde et al., 2006; García-Figueiras et al., 2016).
At the same time, choline is needed for the ACh synthesis,
which acts as an autocrine/paracrine growth factor in various
types of healthy and tumor cells, thus regulating their
proliferation. Several excellent reviews regarding involvement
of NNCS in tumorigenesis have been published recently
(Spindel, 2012; Russo et al., 2014; Campoy et al., 2016). In
particular, lung, melanoma, pancreas, breast, and colon cancers
represent examples, where more details related to cholinergic
autocrine/paracrine loop are available. Detailed analysis of the
expression of NNCS elements in tumors of different histogenesis
revealed that they largely reflected their expression in the original
normal tissue (Spindel, 2012). At the same time, the ACh
synthesis was often enhanced in tumors, and some differences in
AChR expression patterns were observed. In general, α7-nAChR
and M3 mAChR were shown to be the most capable among
AChR to promote cell proliferation and cancer progression. On
the other hand, expression of the α9-nAChR was also described
in breast cancer cells; α5-, β2- and β4-nAChR – in broncho-
pulmonary carcinomas; α3- and α4-nAChR – in pancreatic ductal
adenocarcinoma (reviewed in Russo et al., 2014; Campoy et al.,
2016; Dang et al., 2016).
The involvement of M3 mAChR in cancer progression was
related to autocrine/paracrine ACh production. A variety of
cell types in normal lungs synthesizes and releases ACh, which
acts as a growth factor (Reinheimer et al., 1996). However, the
same cholinergic loop may be also involved in the lung cancers
progression (Song et al., 2003). Indeed, as it was shown by Song
et al. (2003), SCLC cell lines express ChAT, VAChT, CHT1, and
both nAChR and mAChR genes, and they synthesize, secrete
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and degrade ACh. Positive ChAT immunostaining was present
not only in SCLC cell lines, but also in biopsies, derived from
the SCLC. Muscarinic receptor agonists caused a concentration-
dependent intracellular Ca2+ rise, which, in turn, leads to the
activation of Akt and MAPK. This effect was canceled by
subtype-selective mAChR antagonists and siRNA. Multiple M3
antagonists, including 4-diphenyl-acetoxy-N-methyl-piperidine
(4-DAMP), P-F-HHSiD, darifenacin, and tiotropium were shown
to inhibit lung cancer cell proliferation in vitro, and darifenacin
and tiotropium were effective in inhibiting lung cancer growth
in vivo in nude xenograft mice. Thus, among AChR, M3 receptors
were suggested as the most important in the development of
lung cancer (Song et al., 2003, 2007, 2008, 2010). As was
reported earlier, M3 can regulate the activity of E-cadherin and
integrins, which are considered as key factors in cell adhesion and
migration (Williams et al., 1993). In keeping with those findings,
it was demonstrated recently that the M3 AChR promoted
invasion and migration of NSCLC cells through the Akt-
dependent pathway (Lin et al., 2014). The same authors reported
that overexpression of the M3 receptor promotes metastasis and
predicts poor prognosis in NSCLC patients (Lin et al., 2014).
Together with an auto-activation mechanism, dependent on ACh
secretion, the involvement of constitutive ligand-independent
receptor activity was also proposed (Spindel, 2012).
Predominant M3 expression was also demonstrated in
melanoma (Lammerding-Köppel et al., 1997; Boss et al., 2005;
Oppitz et al., 2008), although normal melanocytes were reported
to express all M2–M5 receptors (Buchli et al., 2001). Moreover,
M3 receptors expression is elevated in leading edges of tumors
and in metastases (Lammerding-Köppel et al., 1997; Oppitz et al.,
2008). In accordance with this, it was proposed that the M3
receptors play a pivotal role in the chemotaxis of melanoma cells
(Boss et al., 2005).
There is abundant evidence for a predominant role of M3
receptors in colon cancer. Frucht et al. (1999) demonstrated that
the M3 expression was increased about eight-fold in tumor versus
normal tissue, and that the cholinergic agonist carbamylcholine
stimulated the proliferation of M3-expressing colon carcinoma
cell lines (Yang and Frucht, 2000). These findings were confirmed
by other research groups, who demonstrated that the proliferative
action of the M3 receptors depended partially on the trans-
activation of epithelial growth factor (EGF) receptors (Raufman
et al., 2003; Ukegawa et al., 2003). Later, it was shown that the
M3 receptor knockout mice were resistant to the development
of colon tumors in the azoxymethane-induced colon neoplasia
model (Raufman et al., 2008).
Tumors of different histogenesis also express nAChR, and a
possible role of nAChR in tumor progression was also reported
(reviewed in Russo et al., 2014; Dang et al., 2016; Zhao, 2016).
Since mAChR demonstrate the higher affinity for ACh than
nAChR, the ACh produced by tumors is likely to act primarily
through muscarinic pathways. The situation may change if
some additional factors, like chronic nicotine consumption,
significantly increase the expression of nAChR. Indeed, positive
correlations between nAChR signaling and cigarette smoking
were revealed for lung, pancreatic, and esophageal cancers.
Possible mechanism depicting how chronic nicotine exposure
may affect the profile of nAChR expression in affected tissues,
was proposed recently (Schuller, 2009; Zhao, 2016). α7-nAChR
were suggested to be the most growth stimulatory, whereas
α4β-nAChR are growth inhibitory. Normally, nicotine binds
to α4β-nAChR with a higher affinity than to α7-nAChR. But
chronic exposure to nicotine or nicotine-derived nitrosamines
leads to inactivation (desensitization) of the α4β-nAChR
and simultaneous upregulation of α7-nAChR, wherein the
sensitivity of the latter to nicotine remains unchanged. α7-
nAChR are highly selective for Ca2+ when compared to
others nAChR, and Ca2+ influx seems to be related to the
activation of Akt and MAPK signaling pathways. Besides,
Ca2+ influx triggers plasma membrane depolarization, which
activates voltage-gated Ca2+ channels (but not in lymphocytes,
where they are functionally inactive) and consequently prolongs
Ca2+ influx. Interestingly, proliferative effect of nicotine may
be abolished by darifenacine, an M3-selective antagonist,
indicating that a cross-talk between signaling pathways may
occur. Additionally, human-specific dupα7-nAChR protein
could modify the function and ligand tropism of the normal α7-
nAChR ligand-gated channel. However, expression levels of the
corresponding CHRFAM7A gene in tumors were not evaluated
yet.
Muscarinic Receptors and Drug
Resistance
Gq/11-coupled subtypes of mAChR (M1, M3, and M5) are able to
protect against the apoptotic cell death caused by drug treatment.
CHO cells, which stably express these, but not M2 or M4
receptors, demonstrate a significant inhibition of the etoposide-
mediated caspase-3 activity, phosphatidylserine externalization,
and DNA degradation in the presence of the cholinergic agonist
carbachol. Surprisingly, the protective effect was not related to
the PLC pathway. Instead, the conserved poly basic region in
the C-terminal tail of the M1, M3, and M5 receptors contributes
to the ability of these receptors to mediate a protection against
apoptosis (Budd et al., 2003; Tobin and Budd, 2003).
Cholinergic Elements in Leukemic T
Cells
Numerous lines of evidence exist, demonstrating that healthy
CD4+ T cells possess a cholinergic autocrine loop which regulates
their proliferation. As leukemic T cells often display an enhanced
ACh production and express various AChR, there is even
more reason to suggest an involvement of similar mechanism
in pathogenesis of T-ALL, especially bearing in mind the
establishment of such a mechanism for other tumor types.
Acetylcholine production by T cell lines derived from
leukemic patients (CEM, HSB-2, Jurkat, MOLT-3, and MOLT-
4) is considerably higher when compared to unstimulated MNL,
obtained from healthy donors (Fujii et al., 1996; reviewed in
Kawashima and Fujii, 2004). The highest ACh content was
found for MOLT-3 cell line, derived from a patient in the
relapse phase after the multidrug chemotherapy. It appears not
to be coincidental that MOLT-3 also expresses the CHT1, which
could mediate an efficient uptake of choline needed for the
Frontiers in Pharmacology | www.frontiersin.org 7 August 2016 | Volume 7 | Article 290
fphar-07-00290 August 29, 2016 Time: 12:37 # 8
Dobrovinskaya et al. Targeting Cholinergic Machinery in T-leukemias
ACh synthesis. Considering a TCR-independent proliferation of
leukemic cells and the cross-talk between TCR- and mAChR-
triggering signaling pathways, it is tempting to suggest that ACh,
which is produced in large quantities, may act as an autocrine
signal molecule and contribute to the clonal expansion in T-ALL.
Moreover, ACh produced by T-ALL is not rapidly hydrolyzed,
because AChE activity is drastically decreased in these cells, in
contrast to mature T lymphocytes (Rubinstein et al., 1984). On
the other hand, an increased AChE activity was reported in
total blood and lymphocytes samples, obtained from pediatric
patients, newly diagnosed with T- or B-ALL, whereas it decreased
during the remission period. It could be suggested that the
elevated AChE activity is related to the enhanced ACh content
and represents an adaptation mechanism, but the origin of this
additional AChE activity remains unknown (Battisti et al., 2009).
Presence of the mRNA encoding nicotinic α3, 5, 6, 9, and
10 subunits was reported in acute T-leukemic cell lines CEM
and Jurkat (Peng et al., 2004; Landais et al., 2010). Jurkat, but
not CEM, also expressed α7 (Landais et al., 2010). Comparative
analysis of mAChR expression was undertaken in Jurkat, a very
popular model for studies of the T cell signaling pathways. The
transcriptional profile of mRNA coding for various mAChR
isoforms in Jurkat cells demonstrated a robust M3 expression,
which was approximately threefold higher than that of both M5
and M4, whereas M1 and M2 were undetectable (Alea et al.,
2011). This result agrees with earlier study where expression
of the M3 in Jurkat was evidenced by Northern blot (Kaneda
et al., 1993). In the same work (Kaneda et al., 1993), the effect of
several cholinergic agonists on intracellular Ca2+ level in Jurkat
cells was studied. Nicotine had no effect at all indicating that
nAChR seem not to form functional channels in these cells. On
the other hand, ACh, carbachol, muscarine and M1/M3 agonist
Oxo-M induced transient Ca2+ rise, wherein Oxo-M caused the
greatest effect. McN-A343 (a selective M1 agonist), pilocarpine
(potent M1 agonist) and oxotrimarine (a potent M2 agonist)
had no or only slight effect. Differential inhibitory analyses of
Oxo-M-induced Ca2+ rise with muscarinic antagonists revealed
a functional involvement of the M3 receptor. Transient elevation
of the intracellular Ca2+ was followed by the activation of PLC
and IP3 formation. These data undoubtedly evidenced a specific
importance of M3 receptor in the cholinergic loop of Jurkat
leukemic cells.
More recently, two preliminary studies have reported that
nicotine may still induce α –BTX- sensitive Ca2+ increase in
CEM or Jurkat leukemic T cell lines (Kimura et al., 2003; Landais
et al., 2010). It should be noted that in the first paper only 15%
of CEM cells were shown to respond to nicotine, whereas in the
second one no Ca2+ response was detected in CEM cells, albeit
extremely high (10 mM) nicotine concentration was utilized.
A simple mechanism, where nicotine-induced Ca2+ rise in T
lymphocytes is mediated by Ca2+ influx via a plasma membrane
nAChR was questioned in a more detailed study on Jurkat cells
(Razani-Boroujerdi et al., 2007). Nicotine-induced Ca2+ increase
in these experiments was shown to be independent on external
Ca2+. Hence, it is caused by intracellular Ca2+ release and not by
a Ca2+ influx via nAChR, which appear not to form functional
channels in plasma membrane of T cells (Cui and Li, 2010).
Moreover, α -BTX and methyllycaconitine, two relatively specific
antagonists of α7, α9, and α10 nAChR, instead of inhibition of
the nicotine induced Ca2+ rise, by themselves cause cytosolic
Ca2+ increase similar to that induced by nicotine (Razani-
Boroujerdi et al., 2007). Thus, unexpectedly, these compounds
hit alternative molecular targets in T cells and their use as
functional probes for an active nAChR may be challenged in this
case. Also, intracellular Ca2+ increase reported in the last study
was relatively low (less than 150 nM) and its kinetics showed
significant variations from sample to sample (Razani-Boroujerdi
et al., 2007). Collectively, the above mentioned studies pointed to
a limiting role of nAChRs in Ca2+ signaling in leukemic T cells.
In the human leukemic T cell line CEM, nicotine (0.01–10 µM)
down-regulates mRNA expression for all the nAChR subunits
(reviewed in Kawashima et al., 2012).
Are Cholinergic Pathways Involved in the
Interaction of Leukemic T Cells with their
Microenvironment in Bone Marrow?
The BM microenvironment is known to regulate the properties
of healthy hematopoietic stem cells localized in specific niches.
Two distinct microenvironmental niches, namely “osteoblastic
(endosteal)” and “vascular,” have been identified in the BM.
It was proposed recently that in leukemic individuals these
niches represent specific places, where subsets of leukemic
cells escape the chemotherapy-induced death and acquire a
drug-resistant phenotype. Moreover, there is emerging evidence
that leukemia cells are able to remodel the BM niches into
malignant ones, which may better support neoplastic cell survival
and proliferation (Chiarini et al., 2016). T-ALL cells were
demonstrated to be in a direct stable contact with BM stromal
cells, namely vascular endothelium and osteoblasts, producing
chemokine CXCL12, an important component for the T-ALL
pathogenesis; CXCL12 acts via the CXCR4 receptor, which is
expressed in leukemic cells (Pitt et al., 2015; Passaro et al., 2016).
As T-ALL produce a large quantity of ACh, it may exert a
significant paracrine effect on neighboring stromal cells. Indeed,
both osteoblasts and endothelial cells were reported to express
both nAChR and mAChR (Sato et al., 2010; Behringer and
Segal, 2015). As a model, ACh produced by leukemic T cells
may interact with corresponding receptors on stromal cells and
play an important role in the remodeling of microenvironmental
niches (Figure 2A).
Genetic Aberration in T Leukemias: Are
They Related to the Cholinergic
Machinery?
T leukemogenesis is a multistep process, with different genetic
aberrations interacting in progenitor T cells, to produce
leukemogenic phenotype characterized by differentiation arrest
and enhanced self-renewal and proliferation capacity. Up-
regulation of transcription factors TLX1 (HOX11), TLX3
(HOX11L2), and SIL/TAL1 are the most frequent changes, where
the TLX3 expression was related to an unfavorable outcome
(Graux et al., 2006). For the moment, the data available about
possible involvement of these factors in the up-regulation of
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FIGURE 2 | Hypothetical model of NNCS involvement in T
leukemogenesis. (A) Autocrine and paracrine effect of ACh derived from T
leukemic cell in specific leukemic niche in BM. (B) Network of signaling events
in leukemic T lymphoblasts. It is suggested, that in absence of TCR/CD3
stimulation in leukemic T cells, elevated level of ACh production and
autostimulation through M (1, 3, 5) receptors may play key role in signaling
network. The sustained CRAC-mediated Ca2+ influx is maintained due to K+
efflux via a set of K+-selective channels: voltage-dependent Kv1.3 and small
conductance KCa2.2; TWIK-related tandem pore K+ channel TRESK may be
also recruited being activated by dephosphorylation by CN. Other
abbreviations: NFkB (nuclear factor kappa-light-chain-enhancer of activated B
cells), PKC (protein kinase C), IL (interleukin), C-Fos (proto-oncogene,
transcription factor), CHT1 (high-affinity choline transporter 1), CTL1-5
(intermediate-affinity choline-transporter-like proteins), ChAT (choline
acetyltransferase), AcCoA (acetyl coenzyme A).
cholinergic system are limited. Yet, noteworthy, the expression
of transcription factor TLX3 in prenatal sympathetic neurons
during embryonic development is restricted to the cholinergic
population and the TLX3 deletion results in a loss of some
cholinergic components in these cells (Furlan et al., 2013; Huang
et al., 2013). Thus, TLX3 is apparently required for the acquisition
of a cholinergic phenotype at the late embryonic stage as well
as throughout the prenatal development in mouse sympathetic
neurons. TLX3 repression resulted in the development of a
noradrenergic, instead of cholinergic phenotype (Furlan et al.,
2013). Among 2462 genes, putative TLX3 targets, BCHE (coding
pseudocholinesterase) and CHRFAM7A (coding dupα7), can be
found (Pujato et al., 2014). Whereas, dupα7 is a dominant-
negative regulator of the α7 ion channel function, these data
argue that the expression of functional α7 nAChR may be
decreased in T-ALL with TLX3 up-regulation.
Cholinomirs: A Novel Approach for
Leukemias?
MicroRNAs (miRNAs) are short single-stranded non-coding
RNAs that influence post-transcriptional gene regulation
by affecting the mRNA stability and/or translational
repression of their target mRNAs. They are involved in
several pathophysiological processes, including differentiation,
proliferation, apoptosis, metabolism, hematopoiesis, immune
response, and cancer (Ha, 2011; Liu and Abraham, 2013).
Furthermore, miRNAs are associated with the regulation of the
cholinergic system (Priyadarshini et al., 2013).
Accordingly, miR-132 and miR-186 down-regulate AChE
through mRNA-targeting (Shaked et al., 2009; Maharshak et al.,
2013; Nadorp and Soreq, 2014). In addition, miR-124 mediates
the cholinergic anti-inflammatory action, by inhibiting the pro-
inflammatory cytokines production (Sun et al., 2013). These
miRNAs have been designated as “CholinomiRs,” for being
involved in the cholinergic signaling (Nadorp and Soreq, 2014).
On the other hand, the participation of miRNAs in cancer
development is multifaceted, given that they play a role as tumor
suppressors or tumor promoters, depending on their particular
targets (Chen et al., 2012). Previous reports suggested that
differential miRNA expression has a potential role in leukemias
and is associated with drug resistance, disease progression
and prognosis (Schotte et al., 2012; Bottoni and Calin, 2014).
Recently, an in silico analysis predicted a group of miRNAs that
is able to regulate the AChE expression (Hanin and Soreq, 2011;
Nadorp and Soreq, 2014). Comparative analysis of these miRNAs
with the miRNAs in acute leukemia of different cytogenetic and
molecular subtypes identified the following “CholinomiRs”: miRs
-125b, -196a, -320, -708 in children, and miRs-24, -125b, -181a-
d, and miR-196a in adults (Schotte et al., 2012). Additionally, the
up-regulation of miR-132 in chronic lymphocytic leukemia was
shown to be related to disease progression (Tavolaro et al., 2015)
and the decrease of miR-124 predicted a favorable prognosis in
acute myeloid leukemia (Chen et al., 2014). For these reasons,
“CholinomiRs,” implicated in the T leukemia pathogenesis, may
be attractive targets for future therapeutic strategies.
Cholinergic System may be Involved in
Shaping of Ca2+ Signals in T Leukemias
As it was emphasized in previous chapters, cholinergic and
TCR-triggered signaling pathways interconnect at the point of
the PLC activation, PIP2 hydrolysis, and generation of the two
second messengers, IP3 and diacylglycerol (DAG). Whereas DAG
activates the RAS/PKC pathway, IP3 induces the release of Ca2+
from the ER by activating the IP3R Ca2+-permeable channel.
Strikingly, Ca2+ release from intracellular stores, independent
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of extracellular Ca2+, also takes place upon the stimulation
of T- (here, Jurkat) cells by nicotine. nAChR (here, the α7
isoform) does not form a functional Ca2+-permeable channel,
but acts in an allosteric manner in concert with a functional TCR
and leukocyte-specific tyrosine kinase (Razani-Boroujerdi et al.,
2007).
Depletion of ER Ca2+ stores is sensed by the STIM1 protein,
integrated in the ER membrane, which in turn induces the
opening of ORAI1 (CRAC) channels, located in the plasma
membrane and mediating Ca2+ influx. To maintain Ca2+ influx
through CRAC, the principal Ca2+-selective channel in T cells,
which mediates a current with a substantial inward rectification,
membrane potential needs to be kept negative (hyperpolarized).
Membrane hyperpolarization may be achieved via the activity
of potassium channels. Voltage-dependent Kv1.3 and especially
(due to their relatively high activity at hyperpolarized potentials)
Ca2+-activated KCa3.1 channels are involved (Cahalan and
Chandy, 2009; Feske et al., 2015). Maintenance of negative
membrane potential is also essential for choline uptake by
CHT1, due to a voltage-dependence of the latter (Iwamoto
et al., 2006), which in turn may control the ACh biosynthesis
rate.
In contrast to healthy T cells activated by antigens, clonal
expansion of T leukemic cells is TCR-independent. Nevertheless,
constitutively high levels of Cn activity have been detected in
leukemic cells. As it was mentioned, we suggest that an elevated
ACh production with consequent autocrine stimulation through
AChR may contribute significantly to this process (Figure 2B).
But what about K+ channels, which support, via membrane
hyperpolarization, a sustained Ca2+ influx, required for the Cn
activation? Acute T-ALL Jurkat cell line displays several-fold
lower Kv1.3 channels density; it was reported also that these
cells express small conductance KCa2.2 channels in increased
numbers, compared to the levels of KCa3.1 channels in activated
healthy T cells (reviewed in Dobrovinskaya et al., 2015). Data
from our lab demonstrated that Jurkat cells and other T-leukemic
cell lines as well as blood samples from patients with T-ALL
show the expression of a tandem-pore K+ (K2P) channel TRESK
(Pottosin et al., 2008; Sánchez-Miguel et al., 2013). Data from
other group also revealed the presence of the members of K2P
channels in human T-cells (Meuth et al., 2008; Andronic et al.,
2013).
Noteworthy, TRESK is the only member of the K2P family
which is activated, albeit indirectly, by elevated intracellular
Ca2+, due to the dephosphorylation of several serine residues in
its NFAT -like domain by Cn (Czirják et al., 2004; Han and Kang,
2009; Enyedi and Czirják, 2014). Thus, TRESK is another target
for Cn in leukemic T-cells. In contrast to Ca2+-activated channels
KCa3.1 and KCa2.2, whose activities are ceased immediately after
Ca2+ removal, TRESK stays active until it is rephosphorylated.
Thus, it could support a more robust and sustained Ca2+ signal,
via a positive feedback loop as TRESK and CRAC may support
each other’s activity mutually: TRESK activation by Ca2+- Cn
and CRAC activation by TRESK-mediated hyperpolarization.
Importantly, TRESK activity could be evoked via G protein-
coupled receptor pathway, by activating muscarinic receptors
or inducing Ca2+ release from the ER by IP3 (Czirják et al.,
2004). To summarize, in leukemic T-cells TRESK could be
directly involved into gene expression regulation by NFAT, as
both TRESK and NFAT are activated in the same manner via
Ca2+-dependent dephosphorylation by Cn. Positive feedback
between TRESK and intracellular Ca2+ increase may be further
re-inforced due to the elevated ACh production and autocrine
stimulation through the mAChR ligation (Dobrovinskaya et al.,
2015).
OUTLOOK
Dysregulation in function and expression of the NNCS
components were reported to be important factors in cause
and progression of several types of cancers. Therefore,
pharmacological agents interfering with the NNCS were
suggested to be very promising for the anti-cancer therapy
(Beckmann and Lips, 2013). Evidently, more research is required
to completely elucidate the function of the NNCS in normal
physiology of different tissues and in pathological states. At the
same time, current data may already point to suitable molecular
targets for new therapeutic strategies.
ACh produced by T cell in a healthy organism plays a key
role in the anti-inflammatory pathway (inflammatory reflex).
Furthermore, the autocrine cholinergic loop represents an
important regulatory mechanism during maturation, activation
and proliferation of T cells. Noteworthy, T leukemic cell lines
derived from relapsed T-ALL patients produce significantly
higher levels of ACh in comparison to healthy T cells. In the
absence of TCR-dependent signaling in leukemic cells, elevated
quantities of ACh, as autocrine/paracrine regulator, may play
an important role in shaping of Ca2+ signals and in clonal
expansion. Similar to other types of cancers, some T-cell derived
leukemic lines demonstrated the up-regulation of M3 receptor.
Transcription factor TLX3, up-regulated in more than 50%
of T-ALL (Graux et al., 2006), is crucial for acquisition of
cholinergic machinery (Furlan et al., 2013; Huang et al., 2013).
Altogether, these data indicate that the NNCS is involved in T
leukemogenesis and that its elements may represent a relevant
therapeutic target.
Although, muscarinic antagonists have not been used yet in
clinical practice as anti-cancer drugs, this therapeutic strategy
is considered and has been discussed for future trials. Taking
into account the evidence about a predominant role of M3
receptors in growth of different types of tumors, widespread
clinical use and low toxicity of M3 antagonists, a potential role
of these drugs as adjuvants for cancer therapies looks especially
attractive (reviewed in Spindel, 2012). As was reported recently,
several muscarinic antagonists, already used in the treatment of
genitourinary diseases (e.g., darifenacin, patents US5096890 and
US6106864), have also been demonstrated to arrest the tumor
growth in vivo (Matera and Tata, 2014).
Promising results were also obtained with a new
anticholinergic agent R2HBJJ which has a high affinity for
M1 and M3 AChR. R2HBJJ was designed for the treatment of
peripheral diseases with reduced access to the central nervous
system. It inhibited NSCLC growth by a mechanism, involving
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down-regulation of cyclin D1-CDK4/6-Rb and arrests the cell
cycle in G0/G1 (Hua et al., 2012).
Taking into account these findings, it would be of special
advantage to reveal the effect of muscarinic antagonists on
proliferation and clonal expansion of leukemic cells, with
subsequent study of underling molecular mechanisms. Another
strategy may involve up-regulation of AChE through miRNAs-
dependent mechanism (AntagomiRs), with a resulting increase
of the ACh degradation in the leukemic cells (Figure 2B). Rather
than being used as alternatives, these treatments should be
combined with conventional anti-cancer therapies, in order to
develop flexible multi-drug protocols to combat T-ALL, a rather
heterogeneous and multifaceted disease.
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